

Example MS (NOT to be used as an official publication)

VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. *J*

Cardiovasc Pharmacol. 2005;45(1):53-60.

24. Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagne C,

Couture P. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of

apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked

hypertriglyceridemia. *Metabolism.* 2008;57(2):246-254.

25. Bachorik PS, Ross JW. National Cholesterol Education Program

recommendations for measurement of low-density lipoprotein cholesterol: executive

summary. The National Cholesterol Education Program Working Group on Lipoprotein

Measurement. *Clin Chem.* 1995;41(10):1414-1420.

26. Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose

statin on the human hepatic expression of genes involved in carbohydrate and

triglyceride metabolism. *J Intern Med.* 2011;269(3):333-339.

27. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new

epidemiologic insights. *Curr Opin Cardiol.* 2009;24(4):345-350.

28. Davidson MB, Hu T, Sain G, Hoar B, Stevenson C, Hoogwerf BJ. The

relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a

PreCIS Database Study. *Diabetes Obes Metab.* 2009;11(2):118-122.